Zai Lab Appoints Alan Sandler, M.D., as President, Head of Global Development, Oncology

Rhea-AI Summary

Zai Lab Limited (NASDAQ: ZLAB) has appointed Alan Sandler, M.D., as President and Head of Global Development for Oncology. Sandler, previously of Genentech, will lead the company's global oncology efforts and support its expanding R&D initiatives. His nearly 30 years of experience in oncology includes significant contributions to innovative therapies. CEO Dr. Samantha Du expressed confidence in Sandler's leadership to enhance Zai Lab's oncology pipeline. The company aims to become a prominent global biopharma player while addressing unmet medical needs in cancer and other diseases.

Positive

• Appointment of Alan Sandler, a seasoned oncology expert, adds credibility and leadership to Zai Lab's oncology franchise.
• Sandler's experience in global development and regulatory approval is expected to accelerate the advancement of Zai's oncology pipeline.

Negative

• None.

SHANGHAI and SAN FRANCISCO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced the appointment of Alan Sandler, M.D., to the newly created position of President, Head of Global Development, Oncology, where he will lead global oncology development and related enabling functions to support the Company’s development activities. Dr. Sandler was most recently the Senior Vice President and Global Head of Product Development Oncology at Genentech, a member of the Roche Group. He will report to Dr. Samantha Du, Chief Executive Officer, and serve on the executive team.

“We are delighted to welcome Alan to Zai Lab as we continue to expand globally and strengthen our R&D leadership,” said Dr. Samantha Du, Founder, Chairwoman and CEO of Zai Lab. “Throughout his distinguished career, Alan has made significant contributions as a respected leader in the oncology community, both in industry and through his clinical practice and academic research. Alan has played a key role in the development of many innovative oncology therapies. We look forward to his leadership of our oncology franchise as we advance towards our goal of becoming a leading global biopharma company.”

“I’m very excited to be joining Zai Lab, given its robust pipeline of innovative clinical compounds,” said Dr. Sandler. “I look forward to accelerating the development of Zai’s extensive and differentiated pipeline of oncology compounds, guide them through regulatory review, and bring them as quickly as possible to patients in need in China and around the world. I am also excited about working to identify additional product candidates to further expand Zai’s oncology portfolio.”

Dr. Sandler brings nearly 30 years of oncology and drug development experience across industry and academia. During his tenure at Genentech/Roche, he led the teams responsible for the global development and regulatory approval of several innovative medicines, most recently Tecentriq®. Prior to joining Genentech/Roche, Dr. Sandler served as Professor and Chief of Hematology/Oncology at Oregon Health and Science University. Previously, he served on the faculties of the medical schools of Indiana University and Vanderbilt University. He holds a Doctor of Medicine degree from Rush Medical College. Dr. Sandler completed his training in internal medicine and a fellowship in medical oncology at Yale-New Haven Medical Center. He has published over 300 peer-reviewed publications, articles, abstracts and book chapters.

About Zai Lab

Zai Lab (NASDAQ:ZLAB; HKEX: 9688) is an innovative commercial-stage biopharmaceutical company focused on bringing transformative medicines for cancer and infectious and autoimmune diseases to patients in China and around the world. We aim to address significant unmet medical needs in large, fast-growing segments of the pharmaceutical market. To that end, our experienced team has secured partnerships with leading global biopharmaceutical companies in order to generate a broad pipeline of innovative marketed products and drug candidates. We have also built an in-house team with strong drug discovery and translational research capabilities and are establishing a pipeline of proprietary drug candidates with global rights. Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing and commercializing our portfolio in order to impact human health worldwide.

For additional information about the company, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.

For more information, please contact:

ZAI LAB CONTACTS:

Zai Lab
Billy Cho, CFO
+86 137 6151 2501
billy.cho@zailaboratory.com

Media: Ryo Imai / Robert Flamm, Ph.D.
Burns McClellan, on behalf of Zai Lab
212-213-0006 ext. 315 / 364
rimai@burnsmc.com / rflamm@burnsmc.com

Investors: Pete Rahmer / Mike Zanoni
Endurance Advisors, on behalf of Zai Lab
415-515-9763 / 610-442-8570
prahmer@enduranceadvisors.com / mzanoni@enduranceadvisors.com

Zai Lab Limited

 

FAQ

Who is the new President of Zai Lab?

Alan Sandler, M.D., has been appointed as the new President and Head of Global Development for Oncology at Zai Lab.

What experience does Alan Sandler bring to Zai Lab?

Sandler brings nearly 30 years of oncology and drug development experience, primarily from his previous role at Genentech.

What is Zai Lab's focus following the appointment of Alan Sandler?

Zai Lab aims to strengthen its R&D leadership and enhance the development of its oncology pipeline under Sandler's leadership.

When was Alan Sandler appointed to Zai Lab?

Alan Sandler was appointed to Zai Lab on December 1, 2020.

What are Zai Lab's goals in oncology?

Zai Lab aims to become a leading global biopharma company focused on developing transformative medicines for cancer.